Jump to content

New FDA Approval for Met Exon skipping NSCLC

Recommended Posts

New Drug Approval Alert: FDA approves capmatinib (Tabrecta) for Met Exon 14 skipping NSCLC – a mutation seen in 3%-4% of #NSCLC. A companion diagnostic to identify these mutations has also been given the green light. The approval reinforces the need for more comprehensive biomarker testing to identify rare mutations and drive better outcomes.


Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.